ArticleFrontiers in public health2026
Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States.
Jing He et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.